Implantable cardioverter-defibrillator implantation in non-ischaemic cardiomyopathy: towards individualized risk stratification.

European Journal of Heart FailureVolume 25, Issue 5 p. 751-753 Invited Editorial Implantable cardioverter-defibrillator implantation in non-ischaemic cardiomyopathy: towards individualized risk stratification Saad Javed, Saad Javed Cardiovascular Research Centre, Cardiovascular Magnetic Resonance Unit & Inherited Cardiac Conditions Care Group, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, London, UK National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorBrian P. Halliday, Corresponding Author Brian P. Halliday [email protected] Cardiovascular Research Centre, Cardiovascular Magnetic Resonance Unit & Inherited Cardiac Conditions Care Group, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, London, UK National Heart and Lung Institute, Imperial College London, London, UK Corresponding author. Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Email: [email protected]Search for more papers by this author Saad Javed, Saad Javed Cardiovascular Research Centre, Cardiovascular Magnetic Resonance Unit & Inherited Cardiac Conditions Care Group, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, London, UK National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorBrian P. Halliday, Corresponding Author Brian P. Halliday [email protected] Cardiovascular Research Centre, Cardiovascular Magnetic Resonance Unit & Inherited Cardiac Conditions Care Group, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, London, UK National Heart and Lung Institute, Imperial College London, London, UK Corresponding author. Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Email: [email protected]Search for more papers by this author First published: 30 March 2023 https://doi.org/10.1002/ejhf.2845 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2793. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al.; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375: 1221– 30. 2 Keil L, Chevalier C, Kirchhof P, Blankenberg S, Lund G, Mullerleile K, et al. CMR-based risk stratification of sudden cardiac death and use of implantable cardioverter-defibrillator in non-ischemic cardiomyopathy. Int J Mol Sci. 2021; 22(13):7115. 3Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation. 2017; 136: 215– 31. 4 Di Marco A, Brown P, Mateus G, Faga V, Nucifora G, Claver E, et al. Late gadolinium enhancement and the risk of ventricular arrhythmias and sudden death in NYHA class I patients with non-ischaemic cardiomyopathy. Eur J Heart Fail. 2023; 25: 740– 50. 5Cleland JGF, Halliday BP, Prasad SK. Selecting patients with nonischemic dilated cardiomyopathy for ICDs: myocardial function, fibrosis, and what's attached? J Am Coll Cardiol. 2017; 70: 1228– 31. 6Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging. 2018; 12: 1645– 55. 7Gigli M, Stolfo D, Graw SL, Merlo M, Gregorio C, Nee Chen S, et al. Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants. Circulation. 2021; 144: 1600– 11. 8Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013; 309: 896– 908. 9Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709– 17. 10Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017; 377: 41– 51. 11Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al.; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350(21): 2151– 8. 12Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43: 3997– 4126. Volume25, Issue5May 2023Pages 751-753 ReferencesRelatedInformation